Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT00167310
Show Display Options
Download search resultsDownload the search results for:
NCT00167310 (1 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
Conditions: Schizophrenia;   Schizoaffective Disorder;   Major Depression;   Bipolar Disorder;   Coronary Artery Disease
Interventions: Drug: Eicosapentaenoic acid (omega-3 fatty acid);   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.